How do you manage immune-related toxicity from checkpoint inhibitors that is refractory to initial steroid therapy?
Consensus guidelines recommend the use of steroid therapy for immune related adverse events irAE, and fortunately most toxicities (with the exception of endocrinopathies) are reversible. No prospective data exists on the management of irAE, including steroid refractory irAE. In most cases, we use infliximab, with the exceptions discussed below. In our experience, most patients experience improvement after only one dose, though occasionally patients have required 2 or 3 doses. For steroid refractory hepatitis, infliximab is contraindicated because of its potential hepatotoxic effects. In these cases we have used mycophenolate mofitil with success. For steroid refractory neurologic irAE, we have had anecdotal success with IVIG (Choe JH, et al...
Join for free or sign in to see the full answer